Drug Profile


Alternative Names: APB-231-A2; SK&F 99085; SR-45023A; SR-9223i

Latest Information Update: 04 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator
  • Class Antineoplastics; Bisphosphonates; Osteoporosis therapies
  • Mechanism of Action Antioxidants; Apoptosis stimulants; Farnesoid X-activated receptor modulators; HMG-CoA reductase inhibitors; Osteoclast inhibitors; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Breast cancer; Cancer metastases; Hypercholesterolaemia; Malignant melanoma; Ovarian cancer; Postmenopausal osteoporosis; Prostate cancer

Most Recent Events

  • 04 Feb 2008 Discontinued - Phase-I/II for Postmenopausal osteoporosis treatment in USA (PO)
  • 29 Dec 2004 ILEX Oncology has been acquired by Genzyme Corporation
  • 12 Mar 2004 Discontinued - Phase-I for Cancer metastases in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top